Astex Therapeutics LTD
General
Total Cases7
Active Cases7
Patents90
--
--
--
Ratings
Experience
Grade
Trend
DCT
--
--
--
PTAB
--
--
--
CAFC
--
--
--
Analytics
Cases
Litigated Patents
Ratings Trends
Recent Dockets
Entered | Case | Description |
|---|---|---|
| 09/17/24 | Summons Issued as to Natco Pharma Limited, Natco Pharma USA LLC, Natco Pharma, Inc. (Attachments: # [1] Summons - Natco Ltd., # [2] Summons - Natco USA.)(mws) (Entered: 09/17/2024) | |
| 09/17/24 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (mws) (Entered: 09/17/2024) | |
| 09/17/24 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Otsuka America, Inc., Corporate Parent Otsuka Pharmaceutical Co., Ltd., Other Affiliate Otsuka Holdings Co., Ltd. for Astex Therapeutics, Ltd. filed by Astex Therapeutics, Ltd. (mws) (Entered: 09/17/2024) | |
| 09/16/24 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 07/30/2024. Date of Expiration of Patent: 11/09/2031.Thirty Month Stay Deadline: 1/30/2027. (mws) (Entered: 09/16/2024) | |
| 09/16/24 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,193,732; 9,868,739. (mws) (Entered: 09/16/2024) | |
| 09/16/24 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mws) (Entered: 09/16/2024) | |
| 09/16/24 | COMPLAINT for ANDA / PATENT INFRINGEMENT filed against Natco Pharma Limited, Natco Pharma USA LLC, and Natco Pharma, Inc. (Filing fee $ 405, receipt number ADEDC-4498137.) - filed by Novartis Pharmaceuticals Corporation, Astex Therapeutics, Ltd. (Attachments: # [1] Exhibit A-B, # [2] Civil Cover Sheet)(mws) (Entered: 09/16/2024) | |
| 09/13/24 | Pro Hac Vice Attorney Seth W. Lloyd, Deanne E. Maynard for Novartis Pharmaceuticals Corporation, added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mws) (Entered: 09/13/2024) | |
| 09/13/24 | SO ORDERED, re [159] Motion for Pro Hac Vice Appearance of Attorney Deanne E. Maynard and Seth W. Lloyd filed by Novartis Pharmaceuticals Corporation, Astex Therapeutics Ltd. Ordered by Judge Jennifer L. Hall on 9/13/2024. (ceg) (Entered: 09/13/2024) | |
| 09/12/24 | Pro Hac Vice Fee - Credit Card Payment received for Deanne E. Maynard and Seth W. Lloyd. ( re [159] MOTION for Pro Hac Vice Appearance of Attorney Deanne E. Maynard and Seth W. Lloyd )( Payment of $ 100, receipt number ADEDC-4497376).(Silver, Daniel) (Entered: 09/12/2024) |